PATENT CLAIM ANALYSIS

Application Number: 16019753
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-02
Patent Classification: ["424", "231100"]

Abstract:
The invention relates to methods of treating melanoma using a herpes simplex virus in combination with an immune checkpoint inhibitor.

Claim (Index 22):
The kit according to  claim 4 , wherein the directions to treat stages IIIb to IV melanoma comprise instructions to administer to a patient with stages IIIb to IV melanoma a herpes simplex virus administered by intratumoral injection into injectable cutaneous, subcutaneous, and nodal tumors at a dose of up to 4.0 ml of 10 6  PFU/mL at day 1 of week 1 followed by a dose of up to 4.0 ml of 10 8  PFU/mL at day 1 of week 4, and every 2 weeks thereafter until complete response, and an anti-CTLA-4 antibody administered intravenously at a dose of 3 mg/kg every 3 weeks for 4 infusions beginning after the third dose of the herpes simplex virus.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 94.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14424424', '16068823', '16068816', '15748284', '16068826']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7390802342457056
- 35 USC 102 Novelty (BERT): 0.621245479022827
- Combined Prediction Score: 0.7272967587234177
- Mean Citation Score: 328.87953
- Max Citation Score: 553.5156
- Similarity Product: 537.6451458559511

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test